Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-4 of 4 for your search:
Drug:
recombinant vaccinia-B7.1 vaccine
Find trials that include:
Any drugs shown
Trial Status:
Closed
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase II Randomized Study of Radiotherapy With or Without Vaccination Comprising Recombinant Vaccinia-PSA and rV-B7.1 Plus Recombinant Fowlpox-PSA Vaccine in Patients With Localized Prostate Cancer
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-00-C-0154
, NCI-NMOB-B00-021, NCI-894, 894, NCT00020228
2.
Phase II Randomized Study of Vaccine Containing Recombinant Vaccinia-Prostate-Specific Antigen (PSA) Admixed With rV-B7.1 Plus Recombinant Fowlpox-PSA Vaccine, Sargramostim (GM-CSF), and Interleukin-2 Versus Nilutamide Alone in Patients With Hormone-Refractory Prostate Cancer
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-00-C-0137
, MB-NAVY-99-04, NCI-T99-0097, T99-0097, NCT00020254
3.
Phase II Pilot Randomized Study of Fowlpox (Pox Vector)-Prostate-Specific Antigen Vaccine With or Without Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-02-C-0218
, NCI-5319, 5319, NCT00045227
4.
Phase I Study of Intralesional Recombinant rV-B7.1 Vaccine in Patients With Unresectable Metastatic Melanoma (Summary Last Modified 02/2002)
Phase:
Phase I
Type:
Treatment
Status:
Completed
Age:
Over 18
Sponsor:
NCI
Protocol IDs:
AECM-99-101
, NCI-T99-0006, NCT00004148, T99-0006
Select All on Page
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute